Semax, identified by CAS Number 80714-61-0, is a synthetic peptide that has emerged as a significant compound in neurological research. Structurally, it is a heptapeptide, a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH) known as ACTH(4-10). Its chemical formula is C37H51N9O10S, with a molecular weight of approximately 813.92 g/mol. Supplied typically as a white lyophilized powder, Semax is designed for laboratory research purposes due to its specialized applications in neuroscience.

The research into Semax primarily focuses on its potential to enhance cognitive functions and provide neuroprotection. Scientific studies have demonstrated that Semax can rapidly elevate levels of Brain-Derived Neurotrophic Factor (BDNF) and its receptor, TrkB, within the hippocampus. This mechanism is crucial as BDNF plays a vital role in neuronal survival, growth, and the formation and strengthening of synapses, processes fundamental to learning and memory. Additionally, Semax has been observed to activate dopaminergic and serotonergic brain systems, neurotransmitter pathways critical for mood, motivation, and cognitive processing.

One of the key advantages of Semax in research is its ability to readily cross the blood-brain barrier, allowing it to exert its effects directly within the central nervous system. This property makes it a valuable subject for studies investigating treatments for cognitive disorders, memory impairments, and conditions affecting brain health. Preclinical research has explored Semax's potential in models of stroke, where it has shown promise in facilitating recovery, and in neurodegenerative diseases, where its neuroprotective qualities are of significant interest.

NINGBO INNO PHARMCHEM CO.,LTD. offers Semax for research purposes, emphasizing its high purity and consistent quality, essential for reliable scientific outcomes. Researchers utilize Semax to investigate various aspects of brain function, including its role in attenuating the behavioral effects of chronic stress and its potential anxiolytic-like actions. While Semax is not an FDA-approved drug and its use is confined to laboratory settings, the extensive body of research supports its continued exploration in understanding complex neurological mechanisms. The scientific community is actively engaged in Semax research, seeking to further elucidate its interactions within the brain and its therapeutic possibilities. This ongoing research underscores the importance of compounds like Semax in advancing our knowledge of brain health and developing future interventions.